

Copy of MD7512 Clinical Presentation & Management of Diabetes: Complications & Cardiovascular Disease

View Online



Clinical Presentation & Management of Diabetes:
Complications & Cardiovascular Disease

1.

Holt RIG, Cockram C, Flyvbjerg A, Goldstein BJ. Textbook of Diabetes [Internet]. 5th ed. Somerset: John Wiley & Sons, Incorporated; 2016. Available from: <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

2.

Holt RIG. Textbook of diabetes [Internet]. 4th ed. Chichester: Wiley-Blackwell; 2010. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

3.

International Textbook of Diabetes Mellitus [Internet]. 4th ed. John Wiley & Sons, Incorporated; 2015. Available from: <http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=1895437>

4.

Type 1 diabetes in adults: diagnosis and management | Guidance and guidelines | NICE. Available from: <https://www.nice.org.uk/guidance/ng17>

5.

Type 2 diabetes in adults: management | Guidance and guidelines | NICE. Available from: <https://www.nice.org.uk/guidance/ng28>

6.

Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *The Lancet*. 2017 Feb;

7.

Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. *The Lancet*. 2014 Jan;383(9911):69–82.

8.

Matheus AS de M, Tannus LRM, Cobas RA, Palma CCS, Negrato CA, Gomes M de B. Impact of Diabetes on Cardiovascular Disease: An Update. *International Journal of Hypertension*. 2013;2013:1–15.

9.

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes - ClinicalKey. Available from:
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858717300335>

10.

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes - ClinicalKey [Internet]. Available from:
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947>

11.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. *New England Journal of Medicine*. 2008 Oct 9;359(15):1577–89.

12.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *The Lancet*. 1998 Sep;352(9131):854-65.

13.

Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New England Journal of Medicine*. 2008 Jun 12;358(24):2545-59.

14.

Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia*. 2009 Nov;52(11):2288-98.

15.

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. *New England Journal of Medicine*. 2011 Mar 3;364(9):818-28.

16.

Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *BMJ*. 2010 Jan 8;340(jan08 1):b5444-b5444.

17.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. *New England Journal of Medicine*. 2009 Jan 8;360(2):129-39.

18.

Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2015 Jun 4;372(23):2197-206.

19.

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*. 2008 Jun 12;358(24):2560–72.

20.

Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care*. 2016 May;39(5):694–700.

21.

Giorgino F, Home PD, Tuomilehto J. Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear? *Diabetes Care*. 2016 Aug;39(Supplement 2):S187–95.

22.

Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. *New England Journal of Medicine*. 2008 Feb 7;358(6):580–91.

23.

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *New England Journal of Medicine*. 1993 Sep 30;329(14):977–86.

24.

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. *New England Journal of Medicine*. 2005 Dec 22;353(25):2643–53.

25.

Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JYC, et al. Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. *JAMA*. 2015 Jan 6;313(1).

26.

Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. *Diabetologia*. 2016 Nov;59(11):2298–307.

27.

Bianchi C, Miccoli R, Del Prato S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports*. 2013 Jun;13(3):403–10.

28.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine*. 2015 Nov 26;373(22):2117–28.

29.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2016 Jul 28;375(4):311–22.

30.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ*. 2011 Jul 26;343(jul26 1):d4169–d4169.

31.

Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *The Lancet*. 2009 May;373(9677):1765–72.

32.

Sultan A, Perriard F, Macioce V, Mariano-Goulart D, Boegner C, Daures JP, et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. *Diabetic Medicine*. 2017 Apr 18;

33.

Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine*. 2017 Apr 13;376(15):1407-18.

34.

Sultan A, Perriard F, Macioce V, Mariano-Goulart D, Boegner C, Daures JP, et al. Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study. *Diabetic Medicine*. 2017 Apr 18;

35.

Soliman EZ, Backlund JYC, Bebu I, Orchard TJ, Zinman B, Lachin JM. Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. *Diabetes Care*. 2017 Jun;40(6):793-9.

36.

Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412-418. *Diabetes Care*. 2017 Jun;40(6):809.3-809.

37.

Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. *New England Journal of Medicine*. 2017 Apr 13;376(15):1419-29.

38.

Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine*. 2017 Apr 13;376(15):1407–18.

39.

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine*. 2017 Jul 20;377(3):300–1.

40.

Older antidiabetic drugs | *The British Journal of Cardiology* [Internet]. Available from: <https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/>

41.

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- *ClinicalKey* [Internet]. Available from: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>

42.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2017 Sep 28;377(13):1228–39.

43.

Pickering RJ, Rosado CJ, Sharma A, Buksh S, Tate M, de Haan JB. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. *Clinical & Translational Immunology*. 2018;7(4).

44.

Microvascular Complications and Foot Care. *Diabetes Care*. 2017 Jan;40(Supplement 1):S88–98.

45.

Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. *BMJ*. 2017 Jan 17;

46.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *The Lancet*. 2010 Jun;375(9733):2215-22.

47.

The changing face of diabetes complications - ClinicalKey [Internet]. Available from: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109>

48.

Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care*. 2016 May;39(5):694-700.

49.

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. *New England Journal of Medicine*. 2011 Mar 3;364(9):829-41.

50.

Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: influence of age at onset, diabetes duration and established and novel risk factors. *Archives of Internal Medicine*. 2011 Mar 14;171(5).

51.

Yudkin JS, Richter B, Gale EA. Intensified glucose control in type 2 diabetes—whose agenda? *The Lancet*. 2011 Apr;377(9773):1220–2.

52.

Zhang CY, Sun AJ, Zhang SN, Wu C neng, Fu MQ, Xia G, et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis. *Annals of Medicine*. 2010 May 6;42(4):305–15.

53.

Ele Ferrannini. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. *European Heart Journal* [Internet]. 2015;36(34):2288–96. Available from: <http://eurheartj.oxfordjournals.org/content/36/34/2288>

54.

Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, et al. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. *Diabetes Care*. 2015 Sep;38(9):1777–803.

55.

Bianchi C, Miccoli R, Del Prato S. Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction? *Current Diabetes Reports*. 2013 Jun;13(3):403–10.

56.

Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care*. 2015 Feb;38(2):316–22.

57.

Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine*. 2015 Jun 4;372(23):2197–206.

58.

Cefalu WT, Rosenstock J, LeRoith D, Blonde L, Riddle MC. Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". *Diabetes Care*. 2016 May;39(5):664-7.

59.

Black JA, Sharp SJ, Wareham NJ, Sandbaek A, Rutten GE, Lauritzen T, et al. Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. *British Journal of General Practice*. 2014 Apr 1;64(621):e208-16.

60.

Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia*. 2009 Nov;52(11):2288-98.

61.

Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *The Lancet Diabetes & Endocrinology*. 2017 Jun;5(6):431-7.

62.

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey [Internet]. Available from: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>

63.

Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. *International Journal of Cardiology*. 2010 May;141(2):157-66.

64.

Richard W. Nesto. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? *Clinical Diabetes* [Internet]. 2008;26(1). Available from: <http://go.galegroup.com/ps/i.do?id=GALE|A174972167&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=07d8e79bb8f42665bb52cc5732948c88>

65.

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 2010 Apr 29;362(17):1563-74.

66.

Filippatos T, Tsimihodimos V, Pappa E, Elisaf M. Pathophysiology of diabetic dyslipidaemia. *Current Vascular Pharmacology*. 2017 Feb 1;15(999):1-1.

67.

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. *Atherosclerosis*. 2016 Sep;252:207-74.

68.

White J, Swerdlow DI, Preiss D, Fairhurst-Hunter Z, Keating BJ, Asselbergs FW, et al. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. *JAMA Cardiology*. 2016 Sep 1;1(6).

69.

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - *ClinicalKey* [Internet]. Available from: <https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036>

70.

Hypertension: Clinical Management of Primary Hypertension in Adults | NICE guideline 127. August 2011 [Internet]. Available from: <http://www.nice.org.uk/guidance/cg127>

71.

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 2010 Apr 29;362(17):1575–85.

72.

Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. *The Lancet*. 2012 Aug;380(9841):601–10.

73.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ: British Medical Journal* [Internet]. 1998;317(7160). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28659/>

74.

Whelton PK. Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia. *Archives of Internal Medicine*. 2005 Jun 27;165(12).

75.

Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, et al. Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study. *Circulation: Cardiovascular Quality and Outcomes*. 2012 Mar 1;5(2):153–62.

76.

Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint

reduction in hypertension study (LIFE): a randomised trial against atenolol. *The Lancet*. 2002 Mar;359(9311):1004-10.

77.

Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *The Lancet*. 2005 Sep;366(9489):895-906.

78.

Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. *Journal of the American College of Cardiology*. 2010 Jun;56(1):77-85.

79.

Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *The Lancet*. 2007 Jan;369(9557):201-7.

80.

Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 2010 Apr 29;362(17):1575-85.

81.

Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. *Diabetologia*. 1996 Nov 21;39(12):1646-54.

82.

Bangalore S, Kumar S, Lobach I, Messerli FH. Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials. *Circulation*. 2011 Jun 21;123(24):2799-810.

83.

Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus. *Archives of Internal Medicine*. 2005 Jun 27;165(12).

84.

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey [Internet]. Available from: <https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020>

85.

Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials- ClinicalKey [Internet]. Available from: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998>

86.

Personalised blood pressure ranges in type 2 diabetes?- ClinicalKey [Internet]. Available from: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020>

87.

Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care*. 2017 Mar;40(3):412-8.

88.

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *The Lancet*. 2010 Jul;376(9735):124-36.

89.

Adamsson Eryd S, Svensson AM, Franzén S, Eliasson B, Nilsson PM, Gudbjörnsdottir S. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up. *Diabetic Medicine*. 2017 Mar;34(3):411-8.

90.

Liew G, Mitchell P, Wong TY. Systemic management of diabetic retinopathy. *BMJ*. 2009 Feb 12;338(feb12 1):b441-b441.

91.

Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology*. 2017 Mar 7;

92.

Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology*. 2017 Mar 7;

93.

Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. *British Journal of Ophthalmology*. 2017 Mar 7;

94.

Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412-418. *Diabetes Care*. 2017 Apr 21;

95.

Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Erratum. Diabetic

Retinopathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40:412–418. *Diabetes Care*. 2017 Apr 21;

96.

Rosenberg JB, Tsui I. Screening for Diabetic Retinopathy. *New England Journal of Medicine*. 2017 Apr 20;376(16):1587–8.

97.

Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. *New England Journal of Medicine*. 2017 Apr 20;376(16):1507–16.

98.

Moreton RBR, Stratton IM, Chave SJ, Lipinski H, Scanlon PH. Factors determining uptake of diabetic retinopathy screening in Oxfordshire. *Diabetic Medicine*. 2017 Jul;34(7):993–9.

99.

Melanie Davies. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. *Clinical Pharmacology : Advances and Applications [Internet]*. 2016;8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922775/>

100.

Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Winkelmayr WC, Nally JV. Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. *American Journal of Kidney Diseases*. 2017 Feb;

101.

Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME - *ClinicalKey*. Available from: <https://www.clinicalkey.com/#!/content/journal/1-s2.0-S1262363617300022>

102.

Webb DR, Zaccardi F, Davies MJ, Griffin SJ, Wareham NJ, Simmons RK, et al. Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. *Diabetes/Metabolism Research and Reviews*. 2016;

103.

Çakici N, Fakkal TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine*. 2016 Nov;33(11):1466–76.

104.

Koye DN, Shaw JE, Reid CM, Atkins RC, Reutens AT, Magliano DJ. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. *Diabetic Medicine*. 2017 Feb;

105.

Johal S, Jackson-Spence F, Gillott H, Tahir S, Mytton J, Evison F, et al. Pre-existing diabetes is a risk factor for increased rates of cellular rejection after kidney transplantation: an observational cohort study. *Diabetic Medicine*. 2017 Jun 5;

106.

Clokier M, Greenway AL, Harding K, Jones NJ, Vedhara K, Game F, et al. New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium. *Diabetic Medicine*. 2017 Mar;34(3):305–15.

107.

Game F. Classification of diabetic foot ulcers. *Diabetes/Metabolism Research and Reviews*. 2016 Jan;32:186–94.

108.

Jhamb S, Vangaveti VN, Malabu UH. Genetic and molecular basis of diabetic foot ulcers: Clinical review. *Journal of Tissue Viability*. 2016 Nov;25(4):229–36.

109.

Boulton AJ, Jeffcoate WJ, Jones TL, Ulbrecht JS. International collaborative research on Charcot's disease - 2009. *The Lancet*. 2009 Jan;373(9658):105-6.

110.

Yavuz M, Ersen A, Hartos J, Schwarz B, Garrett AG, Lavery LA, et al. Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration. *Diabetes Care*. 2017 Feb;40(2):e14-5.

111.

P Naidoo. Lower limb complications of diabetes mellitus: a comprehensive review with clinicopathological insights from a dedicated high-risk diabetic foot multidisciplinary team. *The British Journal of Radiology* [Internet]. 2015;88(1053). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743571/>

112.

Diabetic foot problems: prevention and management | Guidance and guidelines | NICE. Available from: <https://www.nice.org.uk/guidance/ng19>

113.

Holt RIG. Understanding of the causes and management of diabetic foot disease. *Diabetic Medicine*. 2017 Mar;34(3):303-4.

114.

Jin D mei, Xu Y, Geng D feng, Yan T bin. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. *Diabetes Research and Clinical Practice*. 2010 Jul;89(1):10-5.

115.

Çakici N, Fakkal TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. *Diabetic Medicine*. 2016 Nov;33(11):1466–76.

116.

Foresta C, Ferlin A, Lenzi A, Montorsi P. The great opportunity of the andrological patient: cardiovascular and metabolic risk assessment and prevention. *Andrology*. 2017 Mar;

117.

Azmi S, Ferdousi M, Alam U, Petropoulos IN, Ponirakis G, Marshall A, et al. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. *Diabetologia*. 2017 Mar 29;

118.

Andersson DP, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M, Holzmann MJ. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. *Heart*. 2017 Mar 9;

119.

Omland T, Randby A, Hrubos-Strøm H, Røsjø H, Einvik G. Relation of Erectile Dysfunction to Subclinical Myocardial Injury. *The American Journal of Cardiology*. 2016 Dec;118(12):1821–5.

120.

Braffett BH, Wessells H, Sarma AV. Urogenital Autonomic Dysfunction in Diabetes. *Current Diabetes Reports*. 2016 Dec;16(12).

121.

Hotaling JM, Sarma AV, Patel DP, Braffett BH, Cleary PA, Feldman E, et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. *Diabetes Care*. 2016 Sep;39(9):1587–93.

122.

Giovanni Corona. Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. PLoS ONE [Internet]. 2016;11(10). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051725/>

123.

Santi D, Granata ARM, Guidi A, Pignatti E, Trenti T, Roli L, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. European Journal of Endocrinology. 2016 Apr;174(4):513-22.

124.

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey [Internet]. Available from: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>

125.

Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey [Internet]. Available from: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>

126.

Malavige LS, Wijesekara P, Ranasinghe P, Levy JC. The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. European Journal of Medical Research. 2015 Dec;20(1).

127.

Hotaling JM, Sarma AV, Patel DP, Braffett BH, Cleary PA, Feldman E, et al. Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes. Diabetes Care. 2016 Sep;39(9):1587-93.

128.

Dhatariya KK, Vellanki P. Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA). *Current Diabetes Reports*. 2017 May;17(5).

129.

Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Prime [Internet]. Available from: https://www.unboundmedicine.com/medline/citation/22586788/Assessing_the_relationship_between_admission_glucose_levels_subsequent_length_of_hospital_stay_readmission_and_mortality_

130.

Dhatariya K, Levy N, Kilvert A, Watson B, Cousins D, Flanagan D, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. *Diabetic Medicine*. 2012 Apr;29(4):420–33.

131.

The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management - ClinicalKey [Internet]. Available from: <https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728>

132.

Scott AR. Management of hyperosmolar hyperglycaemic state in adults with diabetes. *Diabetic Medicine*. 2015 Jun;32(6):714–24.

133.

Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, . Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. *Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges* [Internet]. Available from: <http://www.sciencedirect.com.ezproxy4.lib.le.ac.uk/science/article/pii/S0149291816307792>

134.

Chloe L. Edridge. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE [Internet]. 2015;10(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465495/>

135.

Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care*. 2015 Feb;38(2):316–22.

136.

Minimizing Hypoglycemia in Diabetes: Table 1. *Diabetes Care*. 2015 Aug;38(8):1583–91.

137.

Zaccardi F, Webb DR, Davies MJ, Dhalwani NN, Gray LJ, Chatterjee S, et al. Predicting hospital stay, mortality and readmission in people admitted for hypoglycaemia: prognostic models derivation and validation. *Diabetologia*. 2017 Mar 17;

138.

Zaccardi F, Webb DR, Davies MJ, Dhalwani NN, Housley G, Shaw D, et al. Risk factors and outcome differences in hypoglycaemia-related hospital admissions: A case-control study in England. *Diabetes, Obesity and Metabolism*. 2017 Apr;

139.

Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. *Nature Reviews Endocrinology*. 2016 Feb 19;12(4):222–32.

140.

Umpierrez G, Korytkowski M. Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. *Nature Reviews Endocrinology*. 2016 Feb 19;12(4):222–32.

141.

Micha R, Peñalvo JL, Cudhea F, Imamura F, Rehm CD, Mozaffarian D. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. *JAMA*. 2017 Mar 7;317(9).

142.

Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people. *Diabetes Care*. 2013 Nov 1;36(11):3411–7.

143.

Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovascular Diabetology*. 2015 Dec;14(1).

144.

Nicolucci A, Standl E. Antiplatelet Therapy for Every Diabetic Person? *Diabetes Care*. 2011 May 1;34(Supplement_2):S150–4.

145.

Seidu S, Achana FA, Gray LJ, Davies MJ, Khunti K. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. *Diabetic Medicine*. 2016 Mar;33(3):280–9.

146.

The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check [Internet]. Available from:
http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/

147.

Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. *Diabetic Medicine*. 2017 Mar;34(3):316–27.

148.

Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabetic Medicine*. 2014 Jul;31(7):764–72.

149.

Dana Dabelea. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. *JAMA [Internet]*. 317(8):825–35. Available from: <http://jamanetwork.com/journals/jama/fullarticle/2606400>

150.

Personalised treatment targets in type 2 diabetes patients: The Dutch approach - *ClinicalKey [Internet]*. Available from: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626>

151.

Dwamena F, Holmes-Rovner M, Gaulden CM, Jorgenson S, Sadigh G, Sikorskii A, et al. Interventions for providers to promote a patient-centred approach in clinical consultations. In: *Cochrane Database of Systematic Reviews [Internet]*. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD003267.pub2>

152.

Proceedings of the 5th International DAWN Summit 2014: Acting together to make person-centred diabetes care a reality - *ClinicalKey [Internet]*. Available from: <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S01688227150>

01862

153.

Denig P, Schuling J, Haaijer-Ruskamp F, Voorham J. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. *BMJ*. 2014 Sep 25;349(sep25 6):g5651-g5651.

154.

Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? *Diabetes Care*. 2017 Jul;40(7):813-20.

155.

Kaul S. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. *Diabetes Care*. 2017 Jul;40(7):821-31.

156.

Ritholz MD, MacNeil T, Weinger K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine*. 2017 Jul 13;

157.

Ritholz MD, MacNeil T, Weinger K. Difficult conversations: adults with diabetes and the discussion of microvascular complications. *Diabetic Medicine*. 2017 Oct;34(10):1447-55.

158.

Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ, editors. Textbook of diabetes [Internet]. Fifth edition. Chichester, West Sussex, UK: Wiley Blackwell; 2017. Available from: <http://ezproxy.lib.le.ac.uk/login?url=http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=4769056>

159.

Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?- ClinicalKey [Internet]. Available from:
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>